The paper analyses the impact of the relatively belated move to professionalism in Rugby Union. We use data on match attendance for 3,667 fixtures in European club Rugby over 15 seasons to estimate the effect of competitive balance on attendance. We find that (short- and medium-term) competitive...

The extent of pharmaceutical advertising and promotion can be characterized by a balancing act between profitable demand expansions and potentially unfavorable subsequent regulatory actions. However, this balance also depends on the nature of competition (e.g. monopoly versus oligopoly). In this...

Using data from 1,226 matches played over 18 seasons, we analyse match attendances in the group stages of the European Rugby Cup (ERC). We find that short-run (match) uncertainty had little effect on attendances. This finding is significant as the ERC has been replaced by a new competition which...

The paper presents results from two natural experiments on the impact of revenue sharing and salary caps on competitive balance in sports leagues arising from the introduction of professionalism in Rugby Union in 1995. The first involves the English Premiership, which traditionally applied a...

This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across a large sample of countries. We focus on drugs to treat HIV/AIDS, TB and malaria in middle and low income countries (MLICs), with robustness checks to other therapeutic categories and other...

Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic competition after entry. However, less attention has been paid to pricing behavior in anticipation of brand-to-brand competition. We contribute to this gap in the literature by both...

Drug pricing in the U.S. is a persistently vexing policy problem. While there is agreement among many policy analysts that supra competitive prices are necessary to promote innovation; significant disagreements arise over how much pricing discretion prescription drug manufacturers should be...

We establish four facts concerning competition among U.S. generic drug suppliers, using IQVIA's National Sales PerspectiveTM 2004Q4 – 2016Q3 data. We define a unique product market (“molform”), consisting of the combination of a molecule active ingredient and a route of administration...